ThemenRubriken
MiniRubriken
Head of Section, responsible for high-performance computing and data handling
Senior Manager, European Electricity Policy
Senior Manager, European Regulation
EU Affairs - Online Media Sales Manager
Senior Media Officer / Head of Press relations Team
Policy advisor Economics and Finance
Consultant (Scientist) - EU FP7 Project 'SafeWind'
Psychiatrist, Public Health Expert or Clinical Psychologist
Energy Engineers and Economists (fixed-term contract)
Stellenangebot registrierenEine Studie über den Zugang zu Krebsbehandlungen zeigt, dass innerhalb Europas große Unterschiede zwischen den Ländern bestehen.
Access to cancer care, such as surgery, drugs and radiotherapy, the availability of anti-cancer drugs and medical training differ throughout the EU, states a study published by the European Society for Medical Oncology (ESMO) on 3 October 2006. Even access to information is said to vary from country to country.
The Medical
Oncology
Status in Europe survey has studied and compared countries, for example, on education and training, sub-specialisations of oncology, patterns of care, national guidelines on cancer and clinical research. The study does not provide for a clear ranking of the European countries on the matter, but shows that Iceland, Switzerland, Italy and Germany have the highest number of both oncologists and facilities as to their population size, whereas Eastern European nations have fewer specialist units.
"This is a failure for Europe," said the president of ESMO, Dr Hakan Mellstedt, referring to thousands, perhaps tens of thousands of unnecessary deaths each year due to lack of care.
Cancer
is one of the biggest causes of death in Europe, and remains a major public-health concern. In 2004, 2 million new cases were detected and 1.2 million deaths reported. One in three Europeans is expected to be diagnosed with some form of cancer at some point in their lives. Commission recognises that Europe is characterised by unacceptable inequalities in cancer control and has for this reason launched several projects
to create comparable indicators to monitor cancer.